Candriam S.C.A. Grows Stake in Stryker Co. (NYSE:SYK)

Candriam S.C.A. boosted its stake in shares of Stryker Co. (NYSE:SYK - Free Report) by 40.5% in the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 181,282 shares of the medical technology company's stock after buying an additional 52,291 shares during the period. Candriam S.C.A.'s holdings in Stryker were worth $65,271,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in SYK. Moloney Securities Asset Management LLC bought a new position in Stryker during the 3rd quarter valued at approximately $1,133,000. Marks Group Wealth Management Inc boosted its stake in Stryker by 3.2% during the 3rd quarter. Marks Group Wealth Management Inc now owns 52,936 shares of the medical technology company's stock valued at $19,124,000 after purchasing an additional 1,623 shares during the last quarter. Catalina Capital Group LLC boosted its stake in Stryker by 21.1% during the 3rd quarter. Catalina Capital Group LLC now owns 2,005 shares of the medical technology company's stock valued at $724,000 after purchasing an additional 349 shares during the last quarter. Wisconsin Capital Management LLC boosted its stake in Stryker by 6.2% during the 3rd quarter. Wisconsin Capital Management LLC now owns 1,380 shares of the medical technology company's stock valued at $499,000 after purchasing an additional 80 shares during the last quarter. Finally, Radnor Capital Management LLC purchased a new stake in Stryker during the 3rd quarter valued at $4,623,000. Institutional investors own 77.09% of the company's stock.

Insider Buying and Selling at Stryker

In other news, Director Ronda E. Stryker sold 201,392 shares of Stryker stock in a transaction dated Friday, January 31st. The stock was sold at an average price of $392.24, for a total value of $78,993,998.08. Following the sale, the director now directly owns 3,642,075 shares of the company's stock, valued at approximately $1,428,567,498. The trade was a 5.24 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, Director Allan C. Golston sold 2,458 shares of Stryker stock in a transaction dated Tuesday, February 18th. The stock was sold at an average price of $383.07, for a total value of $941,586.06. Following the completion of the sale, the director now directly owns 14,895 shares in the company, valued at $5,705,827.65. This trade represents a 14.16 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders own 5.90% of the company's stock.

Remove Ads

Stryker Stock Performance

NYSE SYK traded down $3.03 on Friday, hitting $379.28. 1,961,830 shares of the company traded hands, compared to its average volume of 1,209,637. The company has a current ratio of 1.95, a quick ratio of 1.32 and a debt-to-equity ratio of 0.59. The business's 50 day moving average price is $382.45 and its 200-day moving average price is $372.99. The company has a market capitalization of $144.73 billion, a price-to-earnings ratio of 48.88, a P/E/G ratio of 2.93 and a beta of 0.95. Stryker Co. has a 52-week low of $314.93 and a 52-week high of $406.19.

Stryker (NYSE:SYK - Get Free Report) last posted its quarterly earnings results on Tuesday, January 28th. The medical technology company reported $4.01 EPS for the quarter, beating analysts' consensus estimates of $3.87 by $0.14. Stryker had a return on equity of 23.58% and a net margin of 13.25%. During the same quarter in the previous year, the firm earned $3.46 EPS. Equities analysts expect that Stryker Co. will post 13.47 earnings per share for the current year.

Stryker Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Wednesday, April 30th. Shareholders of record on Monday, March 31st will be issued a dividend of $0.84 per share. The ex-dividend date of this dividend is Monday, March 31st. This represents a $3.36 dividend on an annualized basis and a yield of 0.89%. Stryker's dividend payout ratio is presently 43.30%.

Analysts Set New Price Targets

Several analysts have commented on the company. Barclays increased their target price on Stryker from $418.00 to $443.00 and gave the company an "overweight" rating in a research note on Monday, February 10th. Canaccord Genuity Group increased their target price on Stryker from $420.00 to $435.00 and gave the company a "buy" rating in a research note on Wednesday, January 29th. JPMorgan Chase & Co. increased their target price on Stryker from $420.00 to $445.00 and gave the company an "overweight" rating in a research note on Wednesday, January 29th. StockNews.com downgraded Stryker from a "buy" rating to a "hold" rating in a research note on Thursday. Finally, Citigroup restated a "buy" rating and issued a $450.00 price target on shares of Stryker in a research note on Wednesday, February 26th. Five analysts have rated the stock with a hold rating and sixteen have issued a buy rating to the company. According to data from MarketBeat.com, Stryker presently has an average rating of "Moderate Buy" and a consensus target price of $422.15.

Stryker Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.